Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.3K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.3K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.4K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

808
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
808
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

1.5K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.5K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

879
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
879
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond metastases: a mechanism-based guide to misleading ¹³¹I uptake on whole-body scintigraphy.

Annals of nuclear medicine·2026
Same author

The Correlation Between the Presence of <i>BRAF<sup>V600E</sup></i> and <i>TERT</i> Promoter Mutation and the Response to Treatment with Iodine 131 in Differentiated Thyroid Cancer Patients.

Genes·2026
Same author

Glycaemic variability and preserved performance in elite futsal players with type 1 diabetes.

Journal of diabetes science and technology·2026
Same author

Association of Continuous Glucose Monitoring with Glycaemic, Distress, and Quality of Life Outcomes in Insulin-Treated Type 2 Diabetes: A 12-Month Prospective Study.

Medicina (Kaunas, Lithuania)·2026
Same author

Dulaglutide-associated body odor with dechallenge and rechallenge in a patient with type 2 diabetes.

International journal of clinical pharmacology and therapeutics·2026
Same author

Readability of AI-Generated Patient Information on Glucagon-Like Peptide-1 Receptor Agonists.

JMIR bioinformatics and biotechnology·2026

Related Experiment Video

Updated: Mar 17, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.2K

[CROATIAN GUIDELINES FOR THE PHARMACOTHERAPY OF TYPE 2 DIABETES].

Dario Rahelić, Velimir Altabas, Miro Bakula

    Lijecnicki Vjesnik
    |July 23, 2016
    PubMed
    Summary

    Updated Croatian guidelines for type 2 diabetes pharmacotherapy emphasize individualized patient care. Tailoring glycemic targets and medication selection ensures optimal management for all diabetes patients.

    More Related Videos

    Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
    07:30

    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

    Published on: May 10, 2018

    9.8K
    Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
    10:09

    Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

    Published on: May 11, 2015

    10.1K

    Related Experiment Videos

    Last Updated: Mar 17, 2026

    An In Ovo Model for Testing Insulin-mimetic Compounds
    06:09

    An In Ovo Model for Testing Insulin-mimetic Compounds

    Published on: April 23, 2018

    11.2K
    Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
    07:30

    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

    Published on: May 10, 2018

    9.8K
    Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
    10:09

    Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

    Published on: May 11, 2015

    10.1K

    Area of Science:

    • Endocrinology
    • Metabolic Diseases
    • Pharmacotherapy

    Background:

    • The Croatian Association for Diabetes and Metabolic Disorders issued national guidelines for type 2 diabetes in 2011.
    • An update was necessitated by new evidence and increased medication options for type 2 diabetes treatment.

    Purpose of the Study:

    • To revise and update the national guidelines for the pharmacotherapy of type 2 diabetes in Croatia.
    • To incorporate new evidence on medication effectiveness and safety.

    Main Methods:

    • Guidelines developed by the Croatian Association for Diabetes and Metabolic Diseases and other medical professionals.
    • Evidence-based approach utilizing the GRADE system (Grading of Recommendations, Assessment, Development and Evaluation) for evidence levels and recommendation strength.

    Main Results:

    • The guidelines stress an individualized approach to diabetes management.
    • Glycemic targets and pharmacotherapy selection must be personalized based on patient-specific factors.

    Conclusions:

    • Individualized patient management is crucial for effective type 2 diabetes care.
    • Tailoring treatment considers age, disease duration, comorbidities, and complication risks.
    • Practical, rational, and applicable guidelines are of national interest for type 2 diabetes pharmacotherapy.